New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Achieve Life Sciences

Contributing Author

Recent Articles by Achieve Life Sciences

Oct-02	Achieve Life Sciences Announces Granting of New Hire Inducement Awards ACHV GlobeNewswire
Sep-22	Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD ACHV GlobeNewswire
Sep-18	Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer ACHV GlobeNewswire
Sep-11	Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer ACHV GlobeNewswire
Sep-03	Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation ACHV GlobeNewswire
Sep-02	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences ACHV GlobeNewswire
Aug-07	Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program ACHV GlobeNewswire
Jul-29	Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference ACHV GlobeNewswire
Jul-24	Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025 ACHV GlobeNewswire
Jun-30	Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Proposed Underwritten Public Offering ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation ACHV GlobeNewswire
May-28	Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference ACHV GlobeNewswire
May-20	Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake ACHV GlobeNewswire
May-13	Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program ACHV GlobeNewswire
May-06	Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025 ACHV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.